[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500391":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":47,"collaborators":19,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University Hospital, Limoges","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pentoxifylline","EXPERIMENTAL","Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening",[13],"Drug: Pentoxifylline+Tocopherol",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Pentoxifylline+Tocopherol",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Julie USSEGLIO, Dr","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","+33 (0) 555 056 120","julie.usseglio@chu-limoges.fr",[30],{"facility":31,"status":32,"city":33,"state":19,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Limoges university hospital","RECRUITING","Limoges","87042","France","FR",{"type":38,"coordinates":39},"Point",[40,41],1.24759,45.83362,{"lat":41,"lon":40},[44,46],{"name":45,"role":26,"phone":19,"phoneExt":19,"email":28},"Julie USSEGLIO, MD",{"name":45,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":48,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100500391","phase-2-the-pento-protocol-in-medication-related-osteonecrosis-of-the-jaw-100500391",false,"NCT05795647","The PENTO Protocol in Medication-related Osteonecrosis of the Jaw","PENTO","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Current or past treatment with bisphosphonates (oral or IV) and\u002For targeted therapies (denosumab, bevacizumab)\n* Signs and symptoms for more than 8S with confirmation that the signs and symptoms are not of dental origin\n* AAOMS Stage 2 MRONJ\n* For patients of childbearing age, effective contraception is required\n\nExclusion Criteria:\n\n* History of head or neck radiotherapy or maxilla metastases\n* Patients who have received treatment in the past (PENTO or PENTOCLO protocol)\n* Patients who have undergone surgery for their MRONJ within the last 3 months\n* Pregnant or wishing to be pregnant, breastfeeding\n* Patient under palliative care\n* Patient with hypersensitivity to pentoxifylline or tocopherol or to an excipient\n* History of hypersensitivity reaction to penicillins, cephalosporins, or other beta-lactams (and clindamycin or lincomycin if applicable) or excipient of amoxicillin-a. clavulanic or clindamycin\n* History of jaundice\u002Fhepatic injury related to amoxicillin\u002Fclavulanic acid\n* Patient taking oral anticoagulants, or with a history of major bleeding or bleeding disorders\n* Patient taking platelet aggregation inhibitor, theophylline or aminophylline\n* Patient taking methotrexate, probenecid, mycophenolate mofetil, myorelaxant drugs, macrolide or streptogramin antibiotics\n* Patients with hepatic failure or renal failure (Cl \\\u003C 30 mL\u002Fmin),\n* Patient with hypotension (SBP \\\u003C 90 mmHg)\n* Refusal to participate in the study\n* Patient participating in other interventional research that may interfere with the conduct of this research\n* Patient unable to understand the protocol\n* Patient under curatorship or guardianship","ALL","18 Years",{"count":59,"type":60},17,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or targeted therapies. It leads to a significant decrease in quality of life with pain, eating and chewing disorders, and malnutrition. Current treatments are only partially effective. PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary osteoradionecrosis. The objective of this study is to evaluate the proportion of bone recovery in patients receiving PENTO in MRONJ at 12 months.",[66],"Medication-related Osteonecrosis of the Jaw (MRONJ)",[68,69,70,71,72],"MRONJ","pentoxifylline","tocophérol","bone exposure","renutrition","2026-06-23",{"date":75,"type":76},"2026-06-24","ACTUAL",{"date":78,"type":76},"2024-02-29",{"date":80,"type":60},"2028-04-07",{"name":5,"class":6},1]